Hesperos Presenting at Stanford Drug Discovery Symposium 2026
Hesperos, Inc. is excited to announce that our Chief Scientist, James J. Hickman, Ph.D., and Senior Scientist, Kaveena Autar, PhD, are attending the Stanford Drug Discovery Symposium (SDDS 2026). This premier event brings together leading researchers, industry professionals, and innovators to discuss the latest breakthroughs and technologies in drug development.
Poster Presentation: “In Vitro to In Vivo Translatability of Functional Human-on-a-Chip Systems for Digital Twin Modeling”
Kaveena will present Poster #10 that describes how Hesperos’ Human-on-a-Chip® (HoaC) single and multi-organ system platform models bridge the translational gap between preclinical discovery and predicted clinical outcomes to de-risk and accelerate development pipelines in a cost-effective manner. The research describes how integration of the HoaC platform models with advanced, in silico, pharmacokinetic/pharmacodynamic (PK/PD) digital twin modeling can better predict clinical dosing strategies from in vitro readouts. The poster showcases two compelling case studies: (1) an assessment of neurocognitive functional rescue using one of our CNS models and, (2) accurate predictions of clinical dosing regimens using our multi-organ Malaria-on-a-Chip model.
About our Team
James J. Hickman, Ph.D., is Co-Founder and Chief Scientist at Hesperos, Inc. He also is the Founding Director of the NanoScience Technology Center at the University of Central Florida. A pioneer in the MPS field, Dr. Hickman, has spent over 30 years developing functional in vitro systems. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), the National Academy of Inventors, and is the President of the International Microphysiological Systems Society (IMPSS).
Kaveena Autar, PhD is a Senior Scientist, her research focuses on the translatability of functional in vitro systems, with particular emphasis on advanced neuronal studies. She has developed phenotypic models of human induced pluripotent stem cell (hiPSC)-derived cortical neurons to characterize network maturation and disease pathology.
Attending SDDS 2026? We invite you to connect with J and Kaveena to discuss how Hesperos’ platform technology can support and accelerate your drug development programs in an expedient, cost-effective manner.
Link to the Full Program